JPH075457B2
(en)
*
|
1983-08-16 |
1995-01-25 |
ザ ウエルカム フアウンデ−シヨン リミテツド |
Pharmaceutical composition allowing the release of the active ingredient in a controlled manner
|
US4600773A
(en)
*
|
1983-12-01 |
1986-07-15 |
Eli Lilly And Company |
Crystalline cephalexin hydrochloride monohydrate
|
US4624847A
(en)
*
|
1985-04-22 |
1986-11-25 |
Alza Corporation |
Drug delivery device for programmed delivery of beneficial drug
|
ES8800043A1
(en)
*
|
1985-08-16 |
1987-10-16 |
Alza Corp |
Osmotic dispenser
|
US4963141A
(en)
*
|
1985-08-16 |
1990-10-16 |
Alza Corporation |
Dispensing system for administering beneficial agent formulation to ruminants
|
US4704118A
(en)
*
|
1985-08-16 |
1987-11-03 |
Alza Corporation |
Ruminant dispensing device with thermo-activated memory
|
US4723957A
(en)
*
|
1986-02-07 |
1988-02-09 |
Alza Corp. |
System for delivering drug with enhanced bioacceptability
|
US4716496A
(en)
*
|
1986-05-09 |
1987-12-29 |
Eaton Corporation |
Panel-mounted control station housing
|
US4814181A
(en)
*
|
1987-09-03 |
1989-03-21 |
Alza Corporation |
Dosage form comprising fast agent delivery followed by slow agent delivery
|
US4816263A
(en)
*
|
1987-10-02 |
1989-03-28 |
Alza Corporation |
Dosage form for treating cardiovascular diseases comprising isradipine
|
EP0317780B1
(en)
*
|
1987-11-25 |
1992-05-20 |
American Cyanamid Company |
Sustained (controlled) release delivery system for substituted dihydropyridine calcium channel blockers
|
US4837111A
(en)
*
|
1988-03-21 |
1989-06-06 |
Alza Corporation |
Dosage form for dispensing drug for human therapy
|
US4855141A
(en)
*
|
1988-03-25 |
1989-08-08 |
Alza Corporation |
Device comprising means for protecting and dispensing fluid sensitive medicament
|
US4859470A
(en)
*
|
1988-06-02 |
1989-08-22 |
Alza Corporation |
Dosage form for delivering diltiazem
|
US5612059A
(en)
*
|
1988-08-30 |
1997-03-18 |
Pfizer Inc. |
Use of asymmetric membranes in delivery devices
|
IL91398A
(en)
*
|
1988-08-30 |
1994-05-30 |
Pfizer |
Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
|
GR1000270B
(en)
*
|
1988-09-30 |
1992-05-12 |
Alza Corp |
Dose for cardiovascular troubles therapy
|
IL92966A
(en)
*
|
1989-01-12 |
1995-07-31 |
Pfizer |
Dispensing devices powered by hydrogel
|
US5030452A
(en)
*
|
1989-01-12 |
1991-07-09 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
US5108756A
(en)
*
|
1989-01-12 |
1992-04-28 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
EP0408496A3
(en)
*
|
1989-07-12 |
1992-07-01 |
Ciba-Geigy Ag |
Solid dosage form for pharmaceutical substances
|
US4992277A
(en)
*
|
1989-08-25 |
1991-02-12 |
Schering Corporation |
Immediate release diltiazem formulation
|
US5000962A
(en)
*
|
1989-08-25 |
1991-03-19 |
Schering Corporation |
Long acting diltiazem formulation
|
US5067960A
(en)
*
|
1989-12-06 |
1991-11-26 |
Medtronic, Inc. |
Muscle fitness detection by colorimetry
|
US5190763A
(en)
*
|
1990-05-07 |
1993-03-02 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
US5081161A
(en)
*
|
1990-06-15 |
1992-01-14 |
E. I. Du Pont De Nemours And Company |
Process for making shaped articles of a thermoplastic resin having a microcellular structure
|
NZ238867A
(en)
*
|
1990-07-12 |
1993-08-26 |
Alza Corp |
Dosage form for delayed release comprising pharmaceutically active substance and a drug-release hindering means and a second composition which imbibes fluid, expands, and ejects the active substance from the device
|
DK0542926T3
(en)
*
|
1990-08-07 |
1995-05-15 |
Pfizer |
Use of interface polymerized membranes in release devices
|
US5166145A
(en)
*
|
1990-09-10 |
1992-11-24 |
Alza Corporation |
Antiemetic therapy
|
JP2701977B2
(en)
*
|
1990-09-28 |
1998-01-21 |
ファイザー インク |
Dosage form containing hydrophobic medium
|
US5208037A
(en)
*
|
1991-04-22 |
1993-05-04 |
Alza Corporation |
Dosage forms comprising polymers comprising different molecular weights
|
DE69426997T2
(en)
*
|
1993-02-23 |
2001-11-15 |
Heikki Sirkkola |
The use of a calcium preparation in a medicament for the treatment of dairy cows suffering from hypocalcemia
|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
US6287598B1
(en)
*
|
1993-05-28 |
2001-09-11 |
Alza Corporation |
Method for providing sustained antiepileptic therapy
|
HU213407B
(en)
*
|
1993-12-09 |
1997-06-30 |
Egyt Gyogyszervegyeszeti Gyar |
Process for producing tablet with diffusive-osmotic release
|
US5460826A
(en)
*
|
1994-06-27 |
1995-10-24 |
Alza Corporation |
Morphine therapy
|
US5948787A
(en)
|
1997-02-28 |
1999-09-07 |
Alza Corporation |
Compositions containing opiate analgesics
|
DE19962924A1
(en)
|
1999-12-24 |
2001-07-05 |
Bayer Ag |
Substituted oxazolidinones and their use
|
KR101167465B1
(en)
*
|
2000-10-30 |
2012-07-27 |
유로-셀티크 소시에떼 아노뉨 |
Controlled release hydrocodone formulations
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
DE10129725A1
(en)
|
2001-06-20 |
2003-01-02 |
Bayer Ag |
Combination therapy of substituted oxazolidinones
|
DE10300111A1
(en)
|
2003-01-07 |
2004-07-15 |
Bayer Healthcare Ag |
Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide
|
US10213387B2
(en)
|
2003-09-19 |
2019-02-26 |
Sun Pharma Advanced Research Company Ltd. |
Oral drug delivery system
|
WO2005039481A2
(en)
*
|
2003-09-19 |
2005-05-06 |
Sun Pharmaceutical Industries Limited |
Oral drug delivery system
|
US10226428B2
(en)
|
2003-09-19 |
2019-03-12 |
Sun Pharma Advanced Research Company Ltd. |
Oral drug delivery system
|
DE10355461A1
(en)
|
2003-11-27 |
2005-06-23 |
Bayer Healthcare Ag |
Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases
|
DE102004062475A1
(en)
*
|
2004-12-24 |
2006-07-06 |
Bayer Healthcare Ag |
Solid, orally administrable, modified release pharmaceutical dosage forms
|
EP1685841A1
(en)
|
2005-01-31 |
2006-08-02 |
Bayer Health Care Aktiengesellschaft |
Prevention and treatment of thromboembolic disorders
|
DE102005031577A1
(en)
|
2005-07-06 |
2007-01-11 |
Bayer Healthcare Ag |
Pharmaceutical dosage forms containing a combination of nifedipine and / or nisoldipine and an angiotensin II antagonist
|
DE102005045518A1
(en)
|
2005-09-23 |
2007-03-29 |
Bayer Healthcare Ag |
New 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa
|
JP5416408B2
(en)
|
2005-10-04 |
2014-02-12 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
5-chloro-N-({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) -phenyl] -1,3-oxazolidine-5-yl} -methyl) -2- Novel polymorphs and amorphous forms of thiophenecarboxamide.
|
DE102005047561A1
(en)
|
2005-10-04 |
2007-04-05 |
Bayer Healthcare Ag |
Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance
|
DE102008059206A1
(en)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic
|
KR20140069381A
(en)
*
|
2009-06-02 |
2014-06-10 |
다우 글로벌 테크놀로지스 엘엘씨 |
Sustained release dosage form
|
DE102011007272A1
(en)
|
2011-04-13 |
2012-10-18 |
Bayer Pharma Aktiengesellschaft |
Branched 3-phenylpropionic acid derivatives and their use
|
BR112014027618A2
(en)
|
2012-05-07 |
2017-06-27 |
Bayer Pharma AG |
A process for the manufacture of a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil.
|
UY34856A
(en)
|
2012-07-03 |
2013-12-31 |
Bayer Pharma AG |
PHARMACEUTICAL PRESENTATION FORMS CONTAINING 5-CHLORO-N - ({(5S) -2-OXO-3- [4- (3-OXO-4- MORPHOLINYL) -PHENYL] -1,3-OXAZOLIDIN-5-IL} -METIL) -2-THIOFENCARBOXAMIDE
|
JP5941117B2
(en)
*
|
2014-10-17 |
2016-06-29 |
ダウ グローバル テクノロジーズ エルエルシー |
Sustained release formulation
|
JOP20210019A1
(en)
|
2018-07-24 |
2021-01-24 |
Bayer Ag |
Pharmaceutical dosage form which can be administered orally and has modified release
|
US10905667B2
(en)
|
2018-07-24 |
2021-02-02 |
Bayer Pharma Aktiengesellschaft |
Orally administrable modified-release pharmaceutical dosage form
|
CA3107174A1
(en)
|
2018-07-24 |
2020-01-30 |
Bayer Aktiengesellschaft |
Pharmaceutical dosage form which can be administered orally and has modified release
|